November 11, 2011 - S-Nitrosoglutathione Reductase Inhibitors for the Prevention and Treatment of Experimental Colitis
August 28, 2011 - Structure – Activity Relationships of Pyrrole Based S-Nitrosoglutathione Reductase Inhibitors – Carboxamide Modification
July 14, 2011 - Heterozygous Deletion of S-Nitrosoglutathione Reductase in Mice Does Not Increase Nitrosative Inactivation of O6-Alkylguanine-DNA Alkyltransferase or Diethylnitrosamine-induced Hepatocarcinogenesis
May 3, 2011 - Oral S-Nitrosoglutathione Reductase Inhibitors Attenuate Pulmonary Inflammation and Decrease Airspace Enlargement in Experimental Models of COPD
March 27, 2011 - Discovery of S-nitrosoglutathione reductase inhibitors as potential agents to treat asthma, COPD and IBD

GSNO

S-nitrosoglutathione (GSNO)

N30 Pharma - GSNO molecule

GSNO molecule

S-nitrosoglutathione (GSNO) is an endogenous nitrosothiol that plays a critical role in nitric oxide (NO) signaling. GSNO is one of the primary endogenous sources of bioavailable NO. Although GSNO has shown potential as a therapeutic intervention in preclinical models of disease, it is not practical as a drug for several reasons including difficulty in formulation and administration. Furthermore, exogenously applied GSNO does not enter the cell directly, but requires conversion to S-nitrosated cysteine for transport across the cell membrane.

GSNO and NO concentrations are regulated by GSNO reductase (GSNOR), and these small molecules in turn regulate respiratory function by modulating airway tone and pro- and anti-inflammatory responses in the lung. N30 Pharma’s drug development is based on the premise that the inhibition of GSNOR will increase intracellular levels of GSNO by preventing its degradation, particularly in the setting of diseases that have decreased endogenous levels of nitric oxide and/or increased GSNOR activity.

January 24, 2013 - Pharmacological Inhibition of S-Nitrosoglutathione Reductase Improves Endothelial Vasodilatory Function in Rats in vivo
December 28, 2012 - ADH IB Expression, but Not ADH III, Is Decreased in Human Lung Cancer
February 15, 2012 - Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting GSNOR
January 13, 2012 - Structure–activity relationship of pyrrole based GSNOR inhibitors
August 25, 2011 - Preclinical 28-Day Inhalation Toxicity Assessment of S-Nitrosoglutathione
July 26, 2011 - Discovery of potent and novel GSNOR inhibitors devoid of cytochrome P450 activities
April 19, 2011 - Structure–activity relationships of pyrrole based GSNOR inhibitors: Pyrrole regioisomers and propionic acid replacement